



Lamotrigine 50mg / 100mg Tablets

Each Uncoated scored tablet contains:
Lamotrigine.....50 mg
Excipients.....Q.S.

Each Uncoated scored tablet contains:
Lamotrigine.....100 mg
Excipients.....Q.S.

Lamotrigine- 25 Tablets
Lamotrigine- 50 Tablets
Lamotrigine- 100 Tablets
Lamotrigine- 5 DT

Composition

Lamotrigine- 25 Tablets
Each uncoated scored tablet contains Lamotrigine 25 mg

Lamotrigine- 50 Tablets
Each uncoated scored tablet contains Lamotrigine 50 mg

Lamotrigine- 100 Tablets
Each uncoated scored tablet contains Lamotrigine 100 mg

Lamotrigine- 5 DT
Each dispersible tablet contains Lamotrigine 5 mg

Indications

Lamotrigine is indicated as monotherapy as well as an adjunctive therapy in the treatment of partial seizures in adults with epilepsy.

Lamotrigine is also indicated as adjunctive therapy in the generalized seizures of Lennox-Gestaut syndrome in paediatric and adult patients.

Dosage and Administration

Monotherapy with Lamotrigine in patients 3 16 years of age:

Lamotrigine is to be titrated to the targeted dose of 50 mg/day while maintaining the dose of the EIAEDs at a fixed level. The EIAEDs is then gradually withdrawn over a period of 4 weeks.

Recommended maintenance dose of Lamotrigine as Monotherapy is 500 mg/day given in two divided doses.

Dose recommendation for Lamotrigine (mg/day) for adults (over 12 year).			
	Week 1&2	Week 1&2	Usual Maintenance dose
With enzyme-inducing antiepileptic drugs (EIAEDS*) & No valproic acid (VPA)	50 mg/day (once a day)	100 mg/day (two divided doses)	300-500 mg/day (two divided doses). To achieve maintenance, doses may be increased by 100 mg/day every 1 to 2 weeks.
EIAEDS* & valproic acid (VPA)	25 mg every other day.	25 mg (once a day)	100-400 mg/day (two divided doses). To achieve maintenance, doses may be increased by 25-50 mg/day every 1 to 2 weeks.

* e.g. phenytoin, carbamazepine, phenobarbitone and primidone

Note: In patients taking AEDs where the pharmacokinetic interaction with lamotrigine is currently not known, the dose escalation as recommended for lamotrigine with concurrent valproate should be used, thereafter, the dose should be increased until optimal response is achieved.

Because of a risk of rash the initial dose and subsequent dose escalation should not be exceeded.



RECOMMENDED DOSE ESCALATION FOR LAMOTRIGINE (Lamotrigine) FOR CHILDREN AGED 2-12 YEARS (TOTAL DAILY DOSE IN MG/KG BODY WEIGHT/DAY) ON COMBINED DRUG THERAPY			
	Week 1&2	Week 1&2	Usual Maintenance dose
With AED regimen containing VPA	0.15 mg/kg/day (1 or 2 divided doses)	0.3 mg/kg/day (1 or 2 divided doses)	1-5 mg/kg/day (maximum 200 mg/day in 1 or 2 divided doses). To achieve maintenance, doses may be increased by 0.5-1 mg every 1 to 2 weeks.
Added to EIAEDs and without VPA	0.6 mg/ kg/day (two divided doses)	1.2 mg/ kg/day (two divided doses)	5-15 mg/kg (in two divided doses). To achieve maintenance, doses may be increased by 2-3 mg/kg 1 to 2 weeks to a maximum of 400 mg/day.

Lamotrigine as adjunctive therapy

Lamotrigine therapy should be initiated slowly to avoid the occurrence of rash and should be gradually decreased when it is to be discontinued to prevent rebound seizures. Lamotrigine tablets should be swallowed with water.

Discontinuation Strategy:

For patients receiving lamotrigine in combination with other AEDs, a re-evaluation of all AEDs in the regimen should be considered if a change in seizure control or an appearance of worsening of adverse experiences is observed.

If a decision is made to discontinue therapy with lamotrigine, a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) is recommended unless safety concerns require a more rapid withdrawal.

Discontinuing an EIAED should prolong the half-life of lamotrigine; discontinuing VPA should shorten the half-life of lamotrigine.

Contraindications

1. In children below 2 years of age
2. Hypersensitivity to lamotrigine.

Presentation

- Lamotrigine- 25 Blister pack of 10 tablets
- Lamotrigine- 50 Blister pack of 10 tablets
- Lamotrigine- 100 Blister pack of 10 tablets
- Lamotrigine- 5 DT Blister pack of 10 tablets

For Information about Generic Medicines : genericmedicines@tajpharma.com

Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).





THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION.

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "expected", "plan", "goal" believe, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.





About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufactures pharmaceutical formulations and API for India and other countries of world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaXil and Chemixil association the company manufactures and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

The company medicines are present in France, Georgia, Egypt and CIF countries.



Taj Pharmaceuticals Limited
Working For Healthier World™ INDIA



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2011 Taj Pharma Group (India). All rights reserved.



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2011 Taj Pharma Group (India). All rights reserved.

Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.



TAJ

TAJ GROUP
PHARMACEUTICAL
BUSINESS

Further Details Please Visit: www.tajpharma.com



The contents and design of this website, including Authority logos, are the property of the Taj Pharmaceuticals Limited India, and are protected under copyright law and international treaty.

All rights reserved. Except under the conditions described in the Copyright Act 1968 and subsequent amendments, no part of this website may be reproduced or communicated by any process without prior permission in writing from



Copyright © 2004-2011 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice
The products discussed herein may have different product labeling in different countries. The product information provided in this site is intended only for the residents of India.